Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems

OncoImmunology

Volumn 1, Issue 2, 2012, Pages 201-204

  Manjili, Masoud H ^a   Payne, Kyle K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Adoptive cellular therapy; Breast cancer; Common gamma chain cytokines; Immunotherapy; Myeloid derived suppressor cells; NKT cells

Indexed keywords

BRYOSTATIN 1; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; IONOMYCIN;

ADAPTIVE IMMUNITY; ADOPTIVE CELLULAR THERAPY; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; BREAST CANCER; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL REPROGRAMMING; CELL STIMULATION; CELLULAR PARAMETERS; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SUPPRESSOR CELL;

EID: 84883135666     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.2.18113     Document Type: Review

References (28)

1. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin- Cancer Immunol Immunother 2011. In press. http://dx.doi.org/10.1007/s00262-011-1028-0
2. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+ HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70:4335-45; http://dx.doi.org/10.1158/0008-5472.CAN-09-3767
3. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58:49-59; http://dx.doi.org/10.1007/s00262-008-0523-4
4. Mundy-Bosse BL, Thornton LM, Yang HC, Andersen BL, Carson WE. Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. Cell Immunol 2011; 270:80-7; http://dx.doi.org/10.1016/j.cellimm.2011.04.003
5. Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004; 101:10697702; http://dx.doi.org/10.1073/pnas.0403572101
6. Hayakawa Y, Takeda K, Yagita H, Van Kaer L, Saiki I, Okumura K. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol 2001; 166:6012-8
7. Taraban VY,Martin S, Attfield KE, GlennieMJ, Elliott T, Elewaut D, et al. Invariant NKT cells promote CD8+ cytotoxic T cell responses by inducingCD70 expression on dendritic cells. J Immunol 2008; 180:4615-20.
8. Kmieciak M, Basu D, Payne KK, Toor A, Yacoub A, Wang XY, et al. Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J Immunol 2011; 187:708-17; http://dx.doi.org/10.4049/jimmunol.1100502
9. Ko HJ, Lee JM, Kim YJ, Kim YS, Lee KA, Kang CY. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J Immunol 2009; 182:1818-28; http://dx.doi.org/10.4049/jimmunol.0802430
10. Lee JM, Seo JH, Kim YJ, Kim YS, Ko HJ, Kang CY. The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment. Int J Cancer 2011. In press. http://dx.doi.org/10.1002/ijc.26411
11. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005; 102:9571-6; http://dx.doi.org/10.1073/pnas.0503726102
12. Perret R, Ronchese F. Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours? Tissue Antigens 2008; 72:187-94; http://dx.doi.org/10.1111/j.1399-0039.2008.01088.x
13. Berzofsky JA, Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol 2008; 180:3627-35
14. Fleming MD, Bear HD, Lipshy K, Kostuchenko PJ, Portocarero D, McFadden AW, et al. Adoptive transfer of bryostatin-activated tumor-sensitized lymphocytes prevents or destroys tumor metastases without expansion in vitro. J Immunother Emphasis Tumor Immunol 1995; 18:147-55
15. Chin CS, Miller CH, Graham L, Parviz M, Zacur S, Patel B, et al. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumorsensitized lymphocytes. Int Immunol 2004; 16: 1283-94; http://dx.doi.org/10.1093/intimm/dxh130
16. Ariza ME, Ramakrishnan R, Singh NP, Chauhan A, Nagarkatti PS, Nagarkatti M. Bryostatin-1, a naturally occurring antineoplastic agent, acts as a Toll-like receptor 4 (TLR-4) ligand and induces unique cytokines and chemokines in dendritic cells. J Biol Chem 2011; 286: 24-34; http://dx.doi.org/10.1074/jbc.M110.135921
17. Garcia CS, Curiel RE, Mwatibo JM, Pestka S, Li H, Espinoza-Delgado I. The antineoplastic agent bryostatin-1 differentially regulates IFN-gamma receptor subunits in monocytic cells: transcriptional and posttranscriptional control of IFN-gamma R2. J Immunol 2006; 177:2707-16
18. Li H, Wojciechowski W, Dell'Agnola C, Lopez NE, Espinoza-Delgado I. IFN-gamma and T-bet expression in human dendritic cells from normal donors and cancer patients is controlled through mechanisms involving ERK-1/2-dependent and IL-12-independent pathways. J Immunol 2006; 177:3554-63
19. Rosenberg SA, Sportès C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006; 29:313-9; http://dx.doi.org/10.1097/01.cji.0000210386.55951.c2
20. Crawley AM, Katz T, Parato K, Angel JB. IL-2 receptor gamma chain cytokines differentially regulate human CD8+CD127+ and CD8+CD127- T cell division and susceptibility to apoptosis. Int Immunol 2009; 21: 29-42; http://dx.doi.org/10.1093/intimm/dxn120
21. Paiardini M, Cervasi B, Albrecht H, Muthukumar A, Dunham R, Gordon S, et al. Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIVinfected individuals. J Immunol 2005; 174:2900-9
22. Berzofsky JA, Terabe M. A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. Cancer Immunol Immunother 2008; 57:1679-83; http://dx.doi.org/10.1007/s00262-008-0495-4
23. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4:231-7; http://dx.doi.org/10.1038/nri1309
24. Renukaradhya GJ, Khan MA, Vieira M, Du W, Gervay-Hague J, Brutkiewicz RR. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 2008; 111:5637-45; http://dx.doi.org/10.1182/blood-2007-05-092866
25. Tachibana T, Onodera H, Tsuruyama T, Mori A, Nagayama S, Hiai H, et al. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res 2005; 11:7322-7; http://dx.doi.org/10.1158/1078-0432.CCR-05-0877
26. Silk JD,Hermans IF, Gileadi U, Chong TW, Shepherd D, Salio M, et al. Utilizing the adjuvant properties of CD1ddependent NK T cells in T cell-mediated immunotherapy. J Clin Invest 2004; 114:1800-11
27. Liu K, Idoyaga J, Charalambous A, Fujii S, Bonito A, Mordoh J, et al. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med 2005; 202:1507-16; http://dx.doi.org/10.1084/jem.20050956
28. Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat 2010; 123:39-49; http://dx.doi.org/10.1007/s10549-009-0622-8